Archive
526 articles, sorted by publication time.
More than 20 pharmaceutical companies are advancing RNA therapies, showing that these drugs are expanding from a few success cases into a broader R&D landscape; but market entry depends not only on technological imagination, but also on delivery, safety, and repeatable clinical evidence.
The challenges of cell therapy lie not only in the laboratory and hospital ward, but also in whether patients can reach the collection site; a mobile leukapheresis center is seeking to move the earliest threshold of CAR T treatment closer to the community.
Complete response letters affect drug approvals, share prices, and patient expectations; as the FDA temporarily holds back new letters, the issue is not merely the absence of a few documents, but how to establish stable rules between regulatory transparency and commercial confidentiality.
AI protein design is not only searching for new drug targets; it is also moving into cell culture and manufacturing. Bio-Techne’s latest batch of engineered growth factors and cytokines targets the stability and cost issues that become hardest to ignore as cell therapy moves from research toward mass production.
A UK team has applied artificial intelligence to antigen selection for a Crimean-Congo hemorrhagic fever vaccine, opening a new path for a high-risk disease that has long lacked vaccine tools. But from an algorithmic hit to protection in humans, there remains a long distance involving safety, immune responses, and clinical validation.
Vaccinex will present new biomarker results for pepinemab and its concept for a late-stage Phase 2 trial at the AAIC meeting in London; the real message is not only whether the drug shows signs of promise, but whether a non-amyloid pathway can offer an evidence language strong enough to enter a larger trial.
A 2026 R&D pipeline report shows that candidate therapies for osteoarthritis are no longer centered only on pain relief. From intra-articular injections and cell and tissue repair to modulation of inflammatory signals, the industry is trying to rewrite the story of a chronic disease long regarded as something that can only be “managed.”
This collaboration moves AI drug development from slogan to the everyday R&D workflow of a large pharmaceutical company; but before target selection, candidate molecule quality, and clinical translatability are disclosed, it looks more like a stress test of early-stage R&D efficiency.
A licensing deal worth up to $1.9 billion pushes a Chinese drugmaker’s new respiratory drug toward international markets; but the real answer will still have to come from clinical data showing whether it can gain a foothold in the crowded yet still unmet COPD treatment landscape.
Vaccinex will present new biomarker data for pepinemab and plans for a late-stage Phase 2 trial in London; as dementia treatment increasingly moves toward subtyping and combination strategies, this anti-SEMA4D therapy needs to turn mechanistic signals into clearer clinical answers.
If transplanted cells can secrete insulin in the body without requiring long-term immunosuppression to survive, type 1 diabetes treatment will be pushed toward an entirely new balance of risk and evidence.
Beyond anti-amyloid drugs, neuroinflammation and synaptic protection pathways are still seeking a clinical foothold; whether Vaccinex’s new data can support a larger trial will depend not only on whether the signal looks strong, but also on whether patient selection and endpoint design are sufficiently clear.